相关实验视频

Updated: Jun 4, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

普莱克辛D1是晚期前列腺癌的驱动因素和治疗点

Jing Wei¹, Jing Wang^2,3, Wen Guan¹

¹Department of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA, 99202, USA.

EMBO molecular medicine

|January 3, 2025

概括

普莱克辛D1通过促进干度和对治疗的抵抗力来驱动侵略性前列腺癌 (PCa). 用像D1SP这样的抑制剂向PlexinD1显示出治疗晚期转移性割抵抗性前列腺癌 (CRPC) 的前景.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症研究癌症研究

背景情况:

对抗雄激素受体信号抑制剂 (ARSIs) 和转移的侵袭性前列腺癌 (PCa) 了解甚少.
识别转移性割抵抗性前列腺癌 (CRPC) 的关键驱动因素对于开发有效治疗非常重要.

研究的目的:

为了识别新的分子标,驱动积极的PCa表型.
研究PlexinD1在CRPC进展,ARSI耐药性和转移中的作用.
评估PlexinD1作为高级PCa的治疗点.

主要方法:

对人类PCa组织中的PlexinD1表达的分析.
在体外和体内研究,以评估PlexinD1在CRPC中的功能.
涉及AR信号传递,ErbB3,cMet,ERK/AKT和刺通路的机制研究.
对PlexinD1抑制剂D1SP的临床前评估.

主要成果:

高PlexinD1表达与PCa患者的不良临床结果相关.
普莱克辛D1驱动CRPC的攻击性,干性,细胞可塑性和神经内分泌的分化.
在ARSI治疗后,plexinD1升级调节,激活ErbB3/cMet和非正规的 Hedgehog信号.
在临床前模型中,PlexinD1抑制剂D1SP有效地限制了CRPC生长.

结论:

普莱克辛D1是侵袭性,转移性和耐治疗性前列腺癌的关键驱动因素.
普莱克辛D1通过特定的分子通路促进PCa的可塑性和干性.
向PlexinD1代表了晚期前列腺癌的有前途的治疗策略.

关键词:

雄激素受体信号抑制剂信号抑制剂抵抗割的前列腺癌细胞可塑性细胞可塑性神经内分泌的分化在PlexinD1中使用PlexinD1.

更多相关视频

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...